Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy

Abstract Fingolimod is the first oral disease-modifying therapy approved for relapsing forms of multiple sclerosis (MS). Following phosphorylation in vivo , the active agent, fingolimod phosphate (fingolimod-P), acts as a sphingosine 1-phosphate (S1P) receptor modulator, binding with high affinity t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the neurological sciences 2013-05, Vol.328 (1), p.9-18
Hauptverfasser:	Groves, Aran, Kihara, Yasuyuki, Chun, Jerold
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Central Nervous System - drug effects Central Nervous System - metabolism Experimental autoimmune encephalitis Fingolimod Fingolimod Hydrochloride Humans Immunosuppressive Agents - pharmacology Immunosuppressive Agents - therapeutic use Lysophospholipids Multiple sclerosis Multiple Sclerosis - drug therapy Neurology Neuroprotection Propylene Glycols - pharmacology Propylene Glycols - therapeutic use Receptors, Lysosphingolipid - metabolism S1P Sphingosine - analogs & derivatives Sphingosine - pharmacology Sphingosine - therapeutic use Sphingosine 1-phosphate receptor modulator
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!